Philips launches five-year EXIT-CVD project as Philips stock sits below EUR 25 target

Published on 10/16/2026 at 10:20 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Philips stock costs EUR 22.81 on October 16, 2026. Its oral-care board has 12 experts, while EXIT-CVD runs five years.

Philips strategy and numbers

Philips announced a five-year EXIT-CVD research project on October 15, 2026.
Second-quarter 2026 revenue reached EUR 4.36 billion, while net income rose to EUR 384 million.
Philips stock traded at EUR 22.81 at 10:10 a.m. CEST at Lang & Schwarz on October 16, 2026.

Isometrische 3D-Grafik der Wertschöpfungskette von Fabrik bis Weltvertrieb — Koninklijke Philips N.V. (NL0000009538) illustriert isometrische Wertschöpfungskette von Fabrik über Lager bis Medizingeräte-Vertrieb weltweit, Illustration mit AI erstellt.

Philips stock was trading at EUR 22.81 on October 16, 2026, with the company carrying out a five-year cardiovascular research project announced by Philips on October 15. The project is co-funded by the European Union Innovative Health Initiative and industry partners, giving investors a concrete strategy update ahead of the next results date.

The latest company projects

The EXIT-CVD project is designed to run for five years and covers clinical studies intended to improve cardiovascular care across Europe. The announcement adds an operational milestone to Philips' health technology strategy rather than changing its financial guidance.

On October 8, Philips announced a Global Clinical Advisory Board for Philips Sonicare. The board includes 12 international oral healthcare experts, according to Philips.

What does the target imply?

RBC Capital maintained a Hold rating and a EUR 25.00 price target on October 12, 2026, according to Markets Insider. The target sits above the Lang & Schwarz price, while the cautious rating keeps the focus on execution and product quality.

Philips reported revenue of EUR 4.36 billion and net income of EUR 384 million for the second quarter of 2026, compared with EUR 4.34 billion and EUR 240 million in the second quarter of 2025, respectively, according to Markets Insider. The revenue increase was EUR 0.02 billion, while net income rose EUR 144 million year over year.

Dates investors can track

J.P. Morgan kept a Neutral rating and a EUR 23.50 target in its October 8, 2026 study, reported by dpa-AFX. The next quarterly results are scheduled for November 3, 2026, according to the same report.

Stock price and valuation

For investors, the immediate contrast is between a fresh five-year project and analyst targets that remain measured. Philips is listed on Euronext Amsterdam under PHIA and also trades in New York under PHG, according to the company's release.

Philips was trading at EUR 22.81 at Lang & Schwarz on October 16, 2026, at 10:10 a.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Philips stock.